drugset / Trial / NCT00987168
Sandostatine® LP and Hyperinsulinism
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To replace Sandostatine® in three daily subcutaneous injections by a single intramuscular injection of Sandostatine® LP per month in patients with a diffuse form of hyperinsulinism.
Timeline
- Start
- 2009-05
- Primary completion
- 2011-04
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Octreotide | Peptide | 10 mg | Intramuscular |
| Subject | Octreotide | Peptide | 20 mg | Intramuscular |
| Subject | Octreotide | Peptide | 30 mg | Intramuscular |